Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | June 06, 2023 | June 08, 2023 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director · CHIEF EXECUTIVE OFFICER | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OnKure Therapeutics, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05 | Direct | 17,500 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Travere Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 432,886 |
Ending reported balance
After 2026-09-17 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 95,666 · Balance 528,552 Row 2 · 2026-09-15 · Sale · Disposed 63,498 · Balance 465,054 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2: The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 3 · 2026-09-15 · Sale · Disposed 28,796 · Balance 436,258 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3: The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 4 · 2026-09-15 · Sale · Disposed 3,102 · Balance 433,156 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4: The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-09-15 · Sale · Disposed 270 · Balance 432,886 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Row 6 · 2026-09-16 · Exercise / conversion · Acquired 195,841 · Balance 628,727 Row 7 · 2026-09-16 · Sale · Disposed 99,716 · Balance 529,011 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5: The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 8 · 2026-09-16 · Sale · Disposed 96,125 · Balance 432,886 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F6: The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 9 · 2026-09-17 · Exercise / conversion · Acquired 108,493 · Balance 541,379 Row 10 · 2026-09-17 · Sale · Disposed 101,691 · Balance 439,688 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F7: The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 11 · 2026-09-17 · Sale · Disposed 6,802 · Balance 432,886 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F8: The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04 | Direct | 304,334 |
Reported balance
After 2026-09-15 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-15 · Exercise / conversion · Disposed 95,666 · Balance 304,334 F9: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04 | Direct | 108,493 |
Reported balance
After 2026-09-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-16 · Exercise / conversion · Disposed 195,841 · Balance 108,493 F9: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04 | Direct | 0 |
Reported balance
After 2026-09-17 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-09-17 · Exercise / conversion · Disposed 108,493 · Balance 0 F9: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6: The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7: The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F8: The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F9: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 108,493 | $0.00 Strike: $23.34 | $0.00 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · derivative · entry 14 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,493 shares Expires 2029-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 6,802 | $64.95 | $441,795.34 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 11 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F8 · price: The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 101,691 | $64.59 | $6,567,875.94 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 10 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,688 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F7 · price: The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 108,493 | $23.34 | $2,532,226.62 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 9 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 541,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 195,841 | $0.00 Strike: $23.34 | $0.00 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · derivative · entry 13 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,493 Underlying: Common Stock · 195,841 shares Expires 2029-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 96,125 | $63.64 | $6,117,289.26 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 8 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F6 · price: The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 99,716 | $63.26 | $6,307,964.36 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 7 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 529,011 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5 · price: The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 195,841 | $23.34 | $4,570,928.94 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 6 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 628,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 95,666 | $0.00 Strike: $23.34 | $0.00 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · derivative · entry 12 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304,334 Underlying: Common Stock · 95,666 shares Expires 2029-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 270 | $65.31 | $17,633.70 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 5 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 3,102 | $63.64 | $197,421.83 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 4 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 433,156 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4 · price: The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 28,796 | $62.66 | $1,804,222.02 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,258 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 63,498 | $61.99 | $3,936,526.76 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,054 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 95,666 | $23.34 | $2,232,844.44 |
DisclosureSEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 528,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 22,500 | $43.95 | $988,875.00 |
DisclosureSEC source: 0001763494-26-000006 · form4-05062026_080504.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionPerformance-based restricted stock units · Derivative | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001763494-26-000006 · form4-05062026_080504.xml · derivative · entry 4 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F1 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F1 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001763494-26-000006 · form4-05062026_080504.xml · derivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F1 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F1 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001763494-26-000006 · form4-05062026_080504.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 01:48 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 20 | $42.66 | $853.20 |
DisclosureSEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 4 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 01:48 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 7,165 | $41.75 | $299,138.75 |
DisclosureSEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,906 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F4 · price: The weighted average sale price for the transaction reported was $41.75, and the range of prices were between $41.52 and $42.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 01:48 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 56,815 | $41.01 | $2,329,983.15 |
DisclosureSEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 440,071 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $41.01, and the range of prices were between $40.51 and $41.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 13, 2026 Filed Apr 16, 2026 01:48 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 64,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 496,886 F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001763494-26-000004 · form4-04022026_050410.xml · derivative · entry 4 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 25,098 | $31.46 | $789,583.08 |
DisclosureSEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020. F3 · price: The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 34,902 | $30.55 | $1,066,256.10 |
DisclosureSEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,984 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020. F2 · price: The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 60,000 | $15.46 | $927,600.00 |
DisclosureSEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001763494-26-000003 · form4-02242026_040201.xml · derivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 60,000 | $30.10 | $1,805,766.00 |
DisclosureSEC source: 0001763494-26-000003 · form4-02242026_040201.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The weighted average sale price for the transaction reported was $30.0961, and the range of prices were between $30.00 and $30.325. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 60,000 | $15.46 | $927,600.00 |
DisclosureSEC source: 0001763494-26-000003 · form4-02242026_040201.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 33,635 | $32.70 | $1,099,864.50 |
DisclosureSEC source: 0001763494-26-000002 · form4-02032026_090212.xml · nonDerivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F4 · price: The weighted average sale price for the transaction reported was $32.70, and the range of prices were between $32.5248 and $32.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 66,452 | $32.06 | $2,130,451.12 |
DisclosureSEC source: 0001763494-26-000002 · form4-02032026_090212.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,521 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $32.06, and the range of prices were between $31.52 and $32.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 303,600 | $0.00 Strike: $33.10 | $0.00 |
DisclosureSEC source: 0001763494-26-000002 · form4-02032026_090212.xml · derivative · entry 4 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,600 Underlying: Common Stock · 303,600 shares Expires 2036-01-31 F5 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 113,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001763494-26-000002 · form4-02032026_090212.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 532,973 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 01:25 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 51,865 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001763494-26-000001 · form4-01282026_010144.xml · derivative · entry 6 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 51,865 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 01:25 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 51,865 | $30.10 | $1,560,980.91 |
DisclosureSEC source: 0001763494-26-000001 · form4-01282026_010144.xml · nonDerivative · entry 4 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,173 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The weighted average sale price for the transaction reported was $30.097, and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 01:25 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 51,865 | $15.46 | $801,832.90 |
DisclosureSEC source: 0001763494-26-000001 · form4-01282026_010144.xml · nonDerivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 01:25 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 8,135 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001763494-26-000001 · form4-01282026_010144.xml · derivative · entry 5 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,865 Underlying: Common Stock · 8,135 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 01:25 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 8,135 | $30.01 | $244,153.31 |
DisclosureSEC source: 0001763494-26-000001 · form4-01282026_010144.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,173 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The weighted average sale price for the transaction reported was $30.0127, and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 01:25 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 8,135 | $15.46 | $125,767.10 |
DisclosureSEC source: 0001763494-26-000001 · form4-01282026_010144.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:45 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 27,128 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001763494-25-000005 · form4-10302025_041004.xml · derivative · entry 6 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 27,128 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:45 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 27,128 | $30.12 | $817,073.66 |
DisclosureSEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 4 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,173 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The weighted average sale price for the transaction reported was $30.1192, and the range of prices were between $30.00 and $30.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:45 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 27,128 | $15.46 | $419,398.88 |
DisclosureSEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 446,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:45 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 92,872 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001763494-25-000005 · form4-10302025_041004.xml · derivative · entry 5 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,128 Underlying: Common Stock · 92,872 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:45 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 92,872 | $30.38 | $2,821,358.49 |
DisclosureSEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,173 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The weighted average sale price for the transaction reported was $30.379, and the range of prices were between $30.00 and $30.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:45 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 92,872 | $15.46 | $1,435,801.12 |
DisclosureSEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 512,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2025 Filed May 6, 2025 01:53 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 18,924 | $21.05 | $398,350.20 |
DisclosureSEC source: 0001415889-25-012058 · form4-05062025_010542.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,173 F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 02, 2025 Filed May 6, 2025 01:53 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionPerformance-based restricted stock units · Derivative | 18,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012058 · form4-05062025_010542.xml · derivative · entry 3 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,924 Underlying: Common Stock · 18,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F1 · derivative.exercise_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved. F1 · derivative.expiration_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved. Read SEC document |
| May 02, 2025 Filed May 6, 2025 01:53 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 18,924 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-012058 · form4-05062025_010542.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 438,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved. F2 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:23 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 11,375 | $24.04 | $273,455.00 |
DisclosureSEC source: 0001415889-25-003820 · form4-02132025_020239.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,173 F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 01:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 50,691 | $20.21 | $1,024,343.45 |
DisclosureSEC source: 0001415889-25-003065 · form4-02042025_080216.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 430,548 F2 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $20.2076, and the range of prices were between $19.76 and $20.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.